Healthcare

Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) has announced the completion of participant enrollment in its Phase 2a clinical trial for LP-310, a liposomal tacrolimus oral rinse designed to treat oral lichen planus (OLP), a condition that currently has no FDA-approved treatments. This trial, which includes …

CureVac N.V. (Nasdaq: CVAC), a biotechnology company focused on mRNA-based medicines, announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for a Phase 1 clinical study of CVHNLC. This therapy is an mRNA-based precision immunotherapy designed …

Mesoblast (Nasdaq: MESO) has confirmed that its allogeneic cellular products, including Ryoncil® and Revascor®, will be exempt from U.S. tariffs. This exemption is made possible because the company’s products are designated as “U.S. Country of Origin” products. All products are manufactured using U.S. donors …

Telix Pharmaceuticals (ASX/NASDAQ: TLX) has appointed Anne Whitaker as a Non-Executive Director, effective April 7, 2025. Whitaker's appointment brings a wealth of knowledge and experience to the company, stemming from over three decades in the pharmaceutical, biotech, and specialty pharmaceutical sectors.

Long-Lasting Effect:A 400 mg dose sustained a 91.0% reduction for a year and 74.2% reduction for 1.5 years.

Expanded Access:Ryoncil® will be available to 40% of U.S. children covered by Medicaid with steroid-refractory acute graft versus host disease (SR-aGvHD).

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted marketing and manufacturing authorization for Dupixent® (dupilumab) to treat chronic obstructive pulmonary disease (COPD) in adults whose condition is not well-managed with existing therapies. This …